Dry Eye Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The worldwide market for dry eye syndrome treatment is experiencing robust growth, culminating in a total revenue of US$ 5.4 billion in 2024. Projections indicate that by the end of 2031, the market is poised to achieve a substantial valuation of US$ 9 billion.

Strategies to Propel Growth for Dry Eye Syndrome Treatment Manufacturers

Increasing LASIK Surgeries, Expanding R&D Initiatives, and a Surge in Drug Candidates Fuel Business Growth

The dry eye disease market has witnessed notable trends, including a surge in research and development investments, successful clinical trials, and a rising number of new product approvals. Numerous stakeholders are actively engaged in clinical research, exemplified by Reproxalap, a pipeline candidate by Aldeyra Therapeutics, Inc., currently in Phase III trials. Such endeavors hold significant potential to drive revenue within the dry eye syndrome treatment market.

Dry eye syndrome often emerges as a significant side effect following LASIK surgery, prompting prominent manufacturers to focus on developing supplements tailored for post-LASIK dry eye patients. Consequently, the growing number of LASIK surgeries emerges as a key driver fueling market expansion. For instance, data from the American Refractive Surgery Council reveals that more than 30% of patients undergoing eye surgery are likely to develop dry eye syndrome within the first three months.

Factors Constraining Global Sales of Dry Eye Syndrome Treatment

Limited Awareness Hampers Market Expansion

A notable challenge restraining market growth is the lack of public awareness regarding eye health. Many symptoms of dry eye, which can be effectively treated or alleviated with proper diagnosis and medications, remain poorly understood. Patients often fail to seek consultation with ophthalmologists until they encounter severe clinical issues. Consequently, symptoms like redness, inflammation, and other indicators of dry eye are frequently overlooked and misdiagnosed, leading to fewer patients receiving prescription medications.

Impact of COVID-19 on the Global Dry Eye Syndrome Treatment Market

Revenue Impacted by Reduced Sales of Dry Eye Drugs Due to COVID-19

The COVID-19 pandemic had an adverse effect on the sales of dry eye medications. Lockdowns and other restrictions implemented in affected regions to curb the virus's spread led to a significant decline in sales for manufacturers of dry eye medications. For instance, Novartis AG reported a 31.4% drop in sales of its Xiidra dry eye medication, from US$ 104.0 million in the second quarter of 2019 to US$ 79 million in the second quarter of 2020. Additionally, the pandemic substantially reduced the frequency of new eye exams in affected nations, resulting in decreased demand for dry eye medications.

Country-Wise Insights

• U.S. Market Growth: The United States exhibits a robust dry eye syndrome treatment market, driven by a large target population, improved healthcare access, and high treatment adoption rates. The region's market profitability attracts companies, with innovative awareness campaigns further educating the public about early eye treatments.
• U.K. Market Opportunity: High investments in research and development aimed at developing effective treatment options foster growth in the U.K.'s dry eye syndrome treatment market. An aging population and increasing LASIK surgeries contribute to market expansion.
• Indian Market Attractiveness: India, with its substantial population and cost-effective labor, emerges as an attractive market for dry eye disease treatments. Leading competitors have established production facilities in India, with rising healthcare spending and expanding infrastructure fueling growth.
• Chinese Demand Outlook: China's pharmaceutical industry comprises mainly small and medium-sized businesses with limited R&D expenditures. However, pharmaceutical multinationals like AstraZeneca, Novartis, and Novo Nordisk hold significant market shares. Government initiatives aim to consolidate the pharmaceutical industry, which may impact the dry eye syndrome treatment market.

These dynamics offer new opportunities for product launches and market expansion, setting the stage for substantial growth.

Competitive Landscape

Key companies in the dry eye syndrome treatment market are focusing on expanding their product portfolios through ongoing research and development and product launches. They are forming strategic partnerships with mid-sized or smaller players and expanding production facilities to strengthen their market presence and expand their dry eye syndrome treatment product lines. This strategy is anticipated to enhance their sales footprint in the global dry eye syndrome treatment industry.

Key Companies Profiled:

• Allergan Plc.
• Novartis AG
• Otsuka Pharmaceutical Co. Ltd.
• Santen Pharmaceutical Co. Ltd.
• Bausch Health Companies Inc
• Akorn, Inc.
• Johnson & Johnson Inc.
• Thea Pharmaceutical Limited
• OASIS Medical
• Altair Pharmaceutical Inc.
• Boiron USA
• Similasan Corporation
• Scope Ophthalmic Ltd.
• Reckitt Benkiser Group Plc.
• Medicom Healthcare Ltd.
• FDC Limited
• Jamjom Pharmaceutical Co.
• Lupin Limited
• Sentis Pharma Private Limited

Key Segments Covered in Dry Eye Syndrome Treatment Industry Research

By Product:

• Cyclosporine
• Topical Corticosteroids
• Artificial Tears
• Punctal Plugs
• Removable
• Dissolvable
• Omega Supplements
• Others

By Prescription Type:

• Rx
• OTC
• Medical Devices

By Distribution Channel:

• Hospital Pharmacies
• Eye Health Clinics
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

This product will be delivered within 1-3 business days.